INTRODUCTION
There are no clearly established indications for testosterone therapy for women. Nonetheless, clinicians have treated women with testosterone for decades, with the intention of alleviating a variety of symptoms, with uncertain benefits and risks. In most countries, testosterone therapy is prescribed off-label such that women are using either testosterone formulations approved for men with dose modification, or compounded therapies. Because of these issues, there is a compelling case for a global consensus Position Statement on testosterone therapy for women based on the available evidence from placebo/comparator randomized controlled trials (RCTs).
This Position Statement was developed, by consensus between the participating organizations, to inform health-care professionals of the known benefits and potential risks of testosterone therapy for women. The aims were to provide clear guidance as to which women might benefit from testosterone therapy, to identify symptoms, signs, and conditions for which evidence does not support the prescribing of testosterone, to explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm.
METHODS
A Task Force of representatives of leading societies, whose international memberships include clinicians assessing and managing sex steroid therapy for women, was established. The Task Force agreed on the issues that needed to be addressed after which a systematic review and meta-analysis of the benefits and risks of testosterone therapy for women were conducted 1 . The Task Force then met on 17th May 2019 in Berlin, Germany and drafted this consensus position statement.
Recommendations regarding the benefits and risks of testosterone therapy are based on findings from blinded placebo/comparator RCTs, of at least 12 weeks' duration for which data were available for inclusion in meta-analyses 1 
RECOMMENDATIONS

I.
Measurement of testosterone, female sexual dysfunction and endogenous androgen levels (1) Recommendations pertaining to the measurement of circulating testosterone in women (a) Testosterone may act directly via the androgen receptor (AR)/non-genomic androgenic action, or by reduction to the more potent androgen dihydrotestosterone (DHT) and/or aromatization to estradiol and their metabolites.
(b)
Testosterone concentrations decline during the reproductive years 3,4 (Level IIB).
(c)
Testosterone concentrations appear to be maintained in women beyond the age of 65 years, but whether this confers a benefit is yet to be understood 3, 5 (Level IIB).
(d)
Total testosterone can be measured with high accuracy and reproducibility using liquid/gas chromatography and tandem mass spectrometry assays (LC/GC-MS/MS) 6 (Grade B).
(e) Direct assays for the measurement of total and free testosterone are highly unreliable in the female range 6,7 (Grade A).
(f) Reference laboratories should be 'harmonized' with biological standards in co-ordination with the Center for Disease Control 8 (Expert Opinion).
(g) Measurement of testosterone using direct assays in clinical practice is appropriate, if LC/GC-MS/MS is not available, to exclude high baseline concentrations and also to exclude supraphysiological concentrations during treatment (Expert Opinion).
(h) Current research into testosterone physiology and clinical effects should mainly focus on measuring total testosterone as the main biomarker rather than 'free' testosterone, as evidence that 'free' testosterone is the biologically active testosterone fraction is lacking 9 (Expert Opinion). The diagnosis of HSDD in clinical practice should be based on thorough clinical assessment 11 guided by available diagnostic criteria such as ISSWSH 12, 13 or the International Classification of Diseases 11th Edition 14 (Expert Opinion).
(3) Recommendations pertaining to the associations between endogenous androgen concentrations and female sexual function (a) The associations between endogenous androgen concentrations and sexual function in women remain uncertain due to issues relating to the sensitivity and specificity of androgen assays in some studies and insufficient data (Insufficient).
(b)
The physiology of androgens is complex due to their conversion in tissues and possible intracrine metabolism in multiple tissues (Insufficient).
(c)
No cut-off blood level can be used for any measured circulating androgen to differentiate women with and without sexual dysfunction 15 (Grade C).
II.
Recommendations regarding systemic testosterone therapy for postmenopausal women, in doses that approximate physiological testosterone concentrations for premenopausal women, based on findings from meta-analyses of placebo/comparatorcontrolled randomized clinical trials 1, 16 There are insufficient data to make any recommendations regarding the use of testosterone in premenopausal women for treatment of sexual function or any other outcome (Insufficient). 
(b)
Of the studies that have reported musculoskeletal outcomes, the number of included participants has been small, all participants were taking concurrent estrogen therapy and no studies have been in women with osteoporosis.
(c)
The available data do not support an effect of testosterone treatment on bone mineral density at the spine, total hip or femoral neck at 12 months (Level I, Grade A). (e) There is a need for clinical trials to evaluate the impact of testosterone treatment on musculoskeletal tissues (Expert Opinion). 
Testosterone therapy has not been associated with increases in blood pressure, blood glucose or HbA1c levels (Level I, Grade A).
(d)
A non-significant trend for an increased risk of deep venous thrombosis (VTE) has been seen with testosterone therapy; however, the role of concurrent estrogen therapy in possible VTE risk cannot be excluded (Level I, Grade A).
(e) Limited data preclude assessment of the effects of testosterone therapy on myocardial infarction or death (Insufficient data).
(f) RCTs of testosterone therapy have excluded women at high cardiometabolic disease risk;
most have included women taking concurrent estrogen therapy, and all have been of relatively short duration. Therefore, recommendations regarding the effect of physiologic doses of testosterone in postmenopausal women on cardiovascular health are not generalizable to a more 'at-risk' population or to long-term therapy. (c) Data from RCTs are insufficient to assess long-term breast cancer risk (Insufficient data).
There are no data to support the use of testosterone therapy to prevent breast cancer (Insufficient data).
(e) Women with a prior diagnosis of breast cancer were excluded from the randomized trials for HSDD. Caution is recommended for testosterone use in women with hormone-sensitive breast cancer (Expert Opinion). (b) There is an unmet need for the provision and approval of testosterone treatments specific to women, formulated with the aim of approximating physiological testosterone concentrations for premenopausal women (Expert Opinion).
(10) Recommendations regarding testosterone therapy and serious adverse events
(c) Where an appropriate approved female testosterone preparation is not available, off label, prescribing of an approved male formulation is reasonable, provided hormone concentrations are maintained in the physiologic female range (Expert Opinion).
(d) Compounded 'bioidentical' testosterone therapy cannot be recommended for the treatment of HSDD, due to the lack of evidence for efficacy and safety, unless an authorized equivalent preparation is not available (Expert opinion). In the absence of an available approved product, if a compounded product is needed, the compounding pharmacy should be compliant with purity of Active Pharmaceutical Ingredients (API) and Good Manufacturing Practice (GMP) to meet industry standards for quality and safety. Dosing should be limited to achieving testosterone concentrations in the physiologic premenopausal range.
(e) Use of any testosterone preparation that results in supraphysiologic concentrations of testosterone, including pellets and injections, is not recommended (Expert Opinion).
(f) Should a trial of testosterone therapy be given for HSDD, a baseline total testosterone concentration should be measured before commencement, with a repeat level 3-6 weeks after treatment initiation (Level IIA, Grade C).
(g) Patients should be monitored for their clinical response to treatment and assessed for signs of androgen excess with a serum total testosterone level every 6 months, to screen for overuse (Expert opinion).
(h) If no benefit is experienced by 6 months, treatment should be ceased (Level IB, Grade C). (iv) A set of clearly defined core outcomes needs to be established.
(v) There is a need for an instrument to assess sexual function with the following characteristics: general applicability; not disease-specific; high discriminant validity between women diagnosed with FSD and sexually functional women; validated, to measure FSD per se and as an instrument to screen for and diagnose FSD and demonstrating clinically meaningful response to intervention; cover different domains, with each domain comprising several items; translated and back-translated in a variety of languages; satisfies the most stringent assessment to gain approval by regulatory agencies. (e) Studies must be undertaken to establish the longer-term cardiometabolic and breast safety of testosterone therapy for women.
SUMMARY AND KEY MESSAGES
The international panel concluded the only evidence-based indication for testosterone therapy for women is for the treatment of HSDD, with available data supporting a moderate therapeutic effect, in postmenopausal women. There are insufficient data to support the use of testosterone for the treatment of any other symptom or clinical condition, or for disease prevention.
Meta-analyses of the available data show no severe adverse events during physiological testosterone use, with the caveat that women at high cardiometabolic risk were excluded from study populations. The safety of long-term testosterone therapy has not been established.
It was considered of utmost importance that the diagnosis of HSDD involves a full clinical assessment and that other factors contributing to FSD must be identified and addressed before testosterone therapy is initiated 10, 11 . A blood total testosterone level should not be used to diagnose HSDD. Treatment should only be with formulations that achieve blood concentrations of testosterone that approximate premenopausal physiological concentrations. As no approved female product is presently approved by a national regulatory body, male formulations can be judiciously used in female doses and blood testosterone concentrations must be monitored regularly. The panel recommended against the use of compounded testosterone.
The panel highlighted the pressing need for more research into testosterone therapy for women and the development and licensing of products indicated specifically for women.
